Cost-effective prevention of renal failure in type 2 diabetics using losartan

Journal of Medical Economics

Volumn 8, Issue 131-138, 2005, Pages 131-138

  Jönsson, Linus ^a   Carides, George W ^b   Burke, Thomas A ^b,f   Brandt, Ann Sofie ^a   Salonen, Tapani ^c   Schön, Staffan ^d   Weiss, Lars ^e  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d SKARABORG HOSPITAL   (Sweden)

^e Central Hospital   (Sweden)

^f Outcomes Research Inc   (United States)

Author keywords

Costs and cost analysis; Diabetic nephropathy; End stage renal disease; Losartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; LOSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 28244483307     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: 10.3111/200508131138     Document Type: Article

References (19)

1. Svenskt register för aktiv uremivård, Aktiv uremivård i Sverige 1991-1999. SRAU: Skövde, 2000.
2. Zimmet P, McCarty D. The NIDDM epidemic: global estimates and projections. IDF Bulletin 1995; 40: 8-16.
3. National Swedish Board of Health and Welfare. National guidelines for treatment and care of diabetes mellitus. Stockholm: National Swedish Board of Health and Welfare, 1999.
4. King HR, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
5. Jönsson B, Smith U. [Good diabetic control is worthwhile.] Läkartidningen 1997; 94: 2803-2804 [in Swedish].
6. Bretzel RG. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy. Journal of Diabetes and its Complications 1997; 11: 112-122.
7. Nilsson P, Attvall S. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions.] Läkartidningen 2001; 98: 4960-4962 [in Swedish].
8. Brenner BM, Vooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001; 345: 861-869.
9. Sennfalt K, Magnusson M, Carlsson P. Comparison of hemodialysis and peritoneal dialysis - a cost-utility analysis. Peritoneal Dialysis International 2002; 22: 39-47.
10. Jakobsen A. [Costs of care in uremia. How much does kidney transplantation cost?] Tidsskrift for den Norske Lægeforening 1990; 110: 338-341 [in Norwegian].
11. Salonen T, Reina T, Oksa H et al. Cost analysis of renal replacement therapies in Finland. American Journal of Kidney Diseases 2003; 42: 1228-1238.
12. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 2000; 1: 1-15.
13. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall, 1993.
14. Herman WH, Shahinfar S, Carides GW et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26: 683-687.
15. Gerth WC, Remuzzi G, Viberti G et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney International 2002; 62(Suppl 82): 68-72.
16. Gerdtham UG, Jonsson B. Health care expenditure in the Nordic countries. Health Policy 1994; 26: 207-220.
17. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001; 345: 851-860.
18. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001; 345: 870-878.
19. Eberhard R, Dikow R. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes. Annals of Medicine 2002; 34: 507-513.